FIELD: medicine.
SUBSTANCE: method involves transcutaneously introducing testosterone preparation as water-and alcohol gel having (in % by weight) testosterone 0.1-10; isopropyl myristate 0.1-5; ethanol 30-98 and thickener 0.1-5 in combination with type 5 phosphodiesterase inhibitor. Sildenaphil citrate is applied as type 5 phosphodiesterase inhibitor.
EFFECT: enhanced effectiveness of treatment.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ENHANCING OF TESTOSTERONE AND ANALOGOUS STEROID LEVELS IN FEMALES | 2001 |
|
RU2286787C2 |
| ORAL PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE ESTERS AND METHOD FOR TESTOSTERONE SHORTAGE TREATMENT WITH THEIR USE | 2010 |
|
RU2642244C2 |
| TESTOSTERONE COMPOSITIONS | 2012 |
|
RU2613891C2 |
| APPLICATION OF AROMATASE INHIBITOR FOR TREATMENT OF HYPOGONADISM AND RELATED DISEASES | 2012 |
|
RU2628808C2 |
| TRANS-CLOMIPHENE DOSING REGIMEN | 2006 |
|
RU2413508C2 |
| METHODS AND MATERIALS WITH TRANS-CLOMIPHENE FOR TREATMENT OF MALE STERILITY | 2006 |
|
RU2404757C2 |
| METHOD FOR SEXUAL INTEREST (LIBIDO) RECOVERY IN MALES BY PRESCRIBING DIETARY SUPPLEMENTS FOR SEXUAL INTEREST (LIBIDO) RECOVERY IN MALES | 2012 |
|
RU2496491C1 |
| METHODS AND MATERIALS FOR TREATING TESTOSTERONE FAILURE IN MEN | 2002 |
|
RU2297218C2 |
| LONG-CHAIN LIPOSBALANCED ESTERS OF TESTOSTERONE FOR ORAL DELIVERY | 2014 |
|
RU2722592C2 |
| USE OF PHARMACEUTICAL COMPOSITION OF β-CYCLODEXTRIN WITH 9-PHENYL-2,3,4,5,6,7,8,9-OCTAHYDRO-1H-SELENOXANTHENE FOR INCREASING/RESTORING LIBIDO | 2019 |
|
RU2782133C2 |
